vimarsana.com

ப்ரொஃபெஸர் ஆஃப் ஹீமாட்டாலஜி இல் சோர்போன் பல்கலைக்கழகம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

MaaT Pharma Announces Positive Topline Results from Phase 2 HERACLES Clinical Trial with Lead Microbiome Ecosystem Therapy MaaT013 in Patients with Acute Graft-versus-Host Disease

(0) Study meets primary and key secondary objectives with positive impact and favorable overall safety profile in 21 heavily pre-treated and immunocompromised patients with steroid-resistant, gastrointestinal-predominant aGvHD following stem cell transplantation Results in line with previously observed data from a larger patient population treated with MaaT013 as part of an early access program MaaT013 expected to advance into pivotal Phase 3 program MaaT Pharma announced today positive topline results from its Phase 2 clinical trial evaluating lead microbiome ecosystem therapy, MaaT013, in a high-risk patient population with grade III-IV steroid-refractory, gastrointestinal-predominant acute graft-versus-host disease (SR-GI-aGvHD). The study met its primary endpoint of clinical efficacy, demonstrating a combined 33.3% complete response rate (CR) or very good partial response rate (VGPR) at day 28. In addition, the overall response rate (ORR) was 38.1% at day 28 and the be

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.